AP
LLY icon

Arlington Partners’s Eli Lilly LLY Stock Holding History

Arlington Partners’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-359
Closed -$209K – 157
2023
Q4 		$209K Sell
359
-98
-21% -$57.2K 0.06% 86
2023
Q3 		$245K Sell
457
-282
-38% -$145K 0.1% 77
2023
Q2 		$347K Buy
739
+132
+22% +$55.4K 0.05% 105
2023
Q1 		$208K Buy
607
+209
+53% +$70.5K 0.03% 131
2022
Q4 		$146K Buy
398
+99
+33% +$35.1K 0.02% 113
2022
Q3 		$97K Sell
299
-194
-39% -$61.5K 0.04% 137
2022
Q2 		$160K Buy
493
+165
+50% +$49.5K 0.05% 116
2022
Q1 		$94K Buy
328
+29
+10% +$7.46K 0.03% 186
2021
Q4 		$83K Buy
+299
New +$75.8K 0.02% 223
2018
Q3 		– Sell
-228
Closed -$19K – 219
2018
Q2 		$19K Hold
228
– – 0.02% 101
2018
Q1 		$18K Buy
+228
New +$18.4K 0.02% 108

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arlington Partners's LLY Position: Q1 2024 in Review

Arlington Partners sold out of Eli Lilly (LLY) in Q1 2024, closing a stake of 359 shares — an estimated $209K sold.

Arlington Partners first reported a position in LLY in Q1 2018 and held it in 11 quarters. The position peaked at $347K in Q2 2023. 3,460 funds tracked by Wall St. Rank hold LLY as of Q1 2024.

  • Arlington Partners reported no remaining Eli Lilly position as of Q1 2024 after selling out during the quarter.
  • Arlington Partners sold 359 Eli Lilly shares in Q1 2024, an estimated $209K.
  • Arlington Partners first reported a position in Eli Lilly in Q1 2018 and held it in 11 quarters.
  • Arlington Partners's Eli Lilly position peaked at $347K in Q2 2023.
  • 3,460 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2024.

Based on Arlington Partners's 13F filing for Q1 2024, filed 16 Apr 2024.